Ginkgo Bioworks partners with WARF for new GD2 CAR T-cell therapies
Pharmaceutical Technology
APRIL 14, 2023
The company and the researchers, with Professor Krishanu Saha as principal investigator (PI) and Dr Christian Capitini as co-PI, will develop a GD2 CAR T-cell therapeutic candidate to treat neuroblastoma, a cancer type that generally affects young children. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Let's personalize your content